Company Information
CIN
Status
Date of Incorporation
17 August 1998
State / ROC
Hyderabad / ROC Hyderabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
30 September 2023
Paid Up Capital
9,301,000
Authorised Capital
20,000,000
Directors
Reddy Narsimha
Director/Designated Partner
almost 2 years ago
almost 2 years ago
Srinivas Vasireddy
Director/Designated Partner
over 2 years ago
over 2 years ago
Vijayalakshmi Vaithianathan
Director/Designated Partner
over 2 years ago
over 2 years ago
Rahul Nirmal Mukim
Director/Designated Partner
over 2 years ago
over 2 years ago
Mohan Rao Dodda
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Kamal Kishore Sharma
Director/Designated Partner
about 3 years ago
about 3 years ago
Pradip Manilal Kanakia
Director/Designated Partner
over 3 years ago
over 3 years ago
Kalidindi Srihari Raju
Director/Designated Partner
over 4 years ago
over 4 years ago
Bandi Vamsikrishna
Director
over 17 years ago
over 17 years ago
Srinivas Reddy Male
Director
over 18 years ago
over 18 years ago
Venkata Reddy Arumalla
Director
almost 26 years ago
almost 26 years ago
Past Directors
Tarun Garg
Additional Director
over 4 years ago
over 4 years ago
Hari Babu Bodepudi
Additional Director
over 4 years ago
over 4 years ago
Vuppalanchi Ramana Rao .
Director
about 7 years ago
about 7 years ago
Venkata Padmanabha Chandramouli Garimella
Whole Time Director
about 7 years ago
about 7 years ago
Nandachary Mudumbi
Whole Time Director
about 13 years ago
about 13 years ago
Krishna Reddy Pingili
Director
almost 22 years ago
almost 22 years ago
Patents
Provided herein is an improved and industrially advantageous process for the preparation
of highly pure vilazodone or a pharmaceutically acceptable salt thereof.
The present invention provides simple, eco-friendly, cost-effective, reproducible, robust and industrial processes for the preparation of intermediate compound 4-{4-[5(S)-(aminomethyl)-2-oxo-l,3-oxazolidin-3-yl]phenyl}morpholin-3-one(II).
The present invention also provides novel intermediates and their use in the ...
The present invention provides processes for the preparation of 4-{4-[5(S)-(aminomethyl)-2-oxo-l,3-oxazolidin-3-yl]phenyl}morpholin-3-one which are simple, eco-friendly, cost-effective, reproducible, robust and are well amenable on industrial scale.
Provided herein are novel, commercially viable and industrially advantageous processes for the preparation of benzofuran-2-carboxamide derivatives and their intermediates, or a pharmaceutically acceptable salt thereof, in high yield and purity. Provided particularly herein are novel, commercially viable and industri...
Provided herein is an industrially advantageous one-pot process for the preparation of rivaroxaban or a stereochemically isomeric form or a racemic mixture thereof, in high yield and purity, using novel intermediates.
Disclosed herein is a stable amorphous form of vilazodone hydrochloride substantially free of crystalline forms, a process for the preparation, pharmaceutical compositions, and methods of treating thereof. Disclosed also herein are stable amorphous co-precipitates of vilazodone hydrochloride and a pharmaceutically a...
The present invention relates to processes for the synthesis of N-[2-(7-methoxy-l-naphthethyl] acetamide, amorphous form of N-[2-(7-methoxy-l-naphthethyl] acetamide and intermediates thereof.
Provided herein are novel, commercially viable and industrially advantageous processes for the preparation of 1 -[2-[(2,4-dimethylphenyl)sulfanyl]phenyl]piperazine, or a pharmaceutically acceptable salt thereof, using novel intermediates, in high yield and 5 purity.
Disclosed herein are novel, commercially viable and industrially advantageous processes for the preparation of Dabigatran or a salt thereof, in high yield and purity, using novel intermediate compounds.
Provided herein are purification processes for the producing highly pure prucalopride succinate salt. Provided also herein are improved, commercially viable and industrially advantageous processes for the preparation of Prucalopride and its intermediate r compounds including methyl 4-acetylamino-5-chloro-2,3-dihydro...
The present invention relates to a novel stereospecific synthesis of (-)(2S,3S)-1-dimethylamino-3-(3-methoxyphenyl)-2-methyl pentan-3-ol an intermediate in the synthesis of 3-[(lR,2R)-3-(dimethylamino)-l -ethyl -2-methylpropyl]phenol.
Disclosed herein are stable and water-soluble amorphous solid dispersions of Vortioxetine hydrobromide with Hydroxyethyl Cellulose (HEC), methods for the preparation, pharmaceutical compositions, and method of treating thereof. Provided also herein are stable amorphous solid dispersions of Vortioxetine hydrobromide ...
The present invention provides novel crystalline polymorphs of N-[2-amino- -(4-fluorobenzylamino)-phenyl] carbamic acid ethyl ester, processes for their preparation and pharmaceutical compositions comprising them.
Provided herein is a novel, commercially viable and industrially advantageous process for the preparation of Tapentadol or a pharmaceutically acceptable salt thereof, preferably highly pure Tapentadol hydrochloride.
Provided herein are improved, commercially viable and industrially advantageous
processes for the preparation of Linezolid, in high yield and purity, using novel
intermediates.
Provide herein are novel, commercially viable and industrially advantageous processes for the preparation of 2-hexadecyIoxy-6-methyI-4H-3, l-benzoxazin-4 one, and its intermediates, in high yield and purity.
Provided herein are improved, commercially viable and industrially advantageous processes for the preparation of highly pure linezolid crystalline Form III.
Provided herein are improved, commercially viable and industrially advantageous processes for the preparation of Bilastine or a pharmaceutically acceptable salt thereof using novel intermediates, in high yield and purity.
Disclosed j herein are stable amorphous co-precipitates of Flibanserin and a pharmaceutical^ acceptable excipient, methods for the preparation, pharmaceutical compositions, and method of treating thereof.
The present invention relates to improved, commercially viable and industrially advantageous processes for the preparation of 5-Hydroxymethyl-oxazolidin-2-one derivatives or a pharmaceutically acceptable salt thereof using novel intermediates, in high yield and purity.
The present invention relates to processes for the preparation of 4 [3 [4 (6 fluoro 1 2 benzisoxazol 3 yl)piperidino]propoxy] 3 methoxyacetophenone and intermediates thereof. The present invention also provides a process for purifying 4 [3 [4 (6 fluoro 1 2 benzisoxazol 3 yl)piperidino]propoxy] 3 methoxyacetophenone ...
Provided herein are novel, commercially viable and industrially advantageous processes
for the preparation of l-[2-[(2,4-dimethylphenyl)sulfanyl]phenyl]piperazine, or a
pharmaceutically acceptable salt thereof, using novel intermediates, in high yield and
purity.
Disclosed herein is an improved, commercially viable and industrially advantageous process for the preparation of 3-formylmethyl-benzoic acid derivatives, or a salt thereof, using novel intermediates in high yield and purity.
Provided herein are novel, commercially viable and industrially advantageous processes for the preparation of Bilastine or a pharmaceutically acceptable salt thereof using novel intermediates, in high yield and purity.
The present invention provides a novel process for the preparation of iloperidone using a novel intermediate. Thus for example, reacting 4-(3-chloropropoxy)-3-methoxy benzaldehyde with methyl magnesium iodide in ether and the reaction mass was heated for 6 hours at reflux temperature, the mass was cooled to ambient ...
The present invention relates to a novel and commercially viable process for substantially optically pure levorotatory and dextrorotatory enantiomers of cetirizine intermediate, 1-[(4-chlorophenyl)phenylmethyl]piperazine, thereby producing substantially optically pure levorotatory and dextrorotatory enantiomers of c...
The present invention provides a novel process for preparation of 5Âaminomethyl substituted oxazolidinones, key intermediates for oxazolidinone antibacterials including linezolid. Thus, the key intermediate of linezolid is prepared by a) reacting N-[3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyI aniline with p...
The present invention provides processes for the preparation of oxazolidinone derivative 5 -chloro-N-( {(5 S)-2-oxo-3 - [4-(3 -oxo-4-morpholiny l)phenyl] -1,3 -oxazolidin-5 -yl} methyl)-2-thiophene-carboxamide (I).
The present invention relates to processes for the preparation of S(+)-N,N-dimethyl-2-[l-(naphthalenyloxy)ethyl]benzene methanamine and intermediates thereof.
More particularly the present invention relates to preparation of the compound 3(S)-(+)-N,N-dimethylamino-3-phenyl propanol useful as intermediate in the...
The present invention provides an improved process for the preparation of oxazolidine
derivative 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-l,3-oxazolidin-5-yl}methyl)-2-thiophene carboxamide.
The present invention provides a cost-effective, reproducible and industrial process for
the preparation of N-[2-(7-methoxy-l-naphthyl) ethyl] acetamide crystalline form I and
pharmaceutical compositions thereof.
The present invention related to novel processes for the preparation of iron (III) carboxymaltose complex. Thus, for example, heating a mixture of one or more maltodextrins, ferric hydroxide and water, oxidizing the iron maltodextrin complex obtained using an aqueous sodium hypochlorite solution and maintaining at...
ABSTRACT
The present invention provides processes for the preparation of intermediates of N-[2-(7-methoxy-1-naphthyl) ethyl] acetamide.
More particularly the present invention relates to processes for the preparation of the compound of structural formula II
Where R is C= N, CH2-NH-COCH3 Also provides Isolated ...
ABSTRACT:
The present invention relates to a process for the preparation of N-[2[(acetylthio) methyl]-1-oxo-3-phenylpropyl] glycine phenyl methyl ester and intermediates thereof.
More particularly the present invention relates to a process for the preparation of intermediate compound 2-(benzyl acrylolyl amino) ace...
The present invention provides racemic dapoxetine solid, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides S-enantiomer of dapoxetine solid, process for its preparation and pharmaceutical compositions comprising it.
Disclosed herein are stable amorphous coprecipitates of rivaroxaban and a pharmaceutically acceptable excipient, methods for the preparation, pharmaceutical compositions, and method of treating thereof
Provided herein are improved, commercially viable and industrially advantageous processes for the preparation of (5R)-5-(hydroxymethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone using novel intermediates.
Provided herein are novel commercially viable and industrially advantageous processes for the preparation of Agomelatine or a salt thereof in high yield and purity using novel intermediates.
Provided herein are improved, commercially viable and consistently reproducible processes for the preparation of highly pure crystal Modification I of Rivaroxaban, which is free from other polymorphs and undesired solvated forms. Provided also herein is a highly pure and stable crystal Modification I of Rivaroxaba...
Disclosed herein is a consistently reproducible process for the production of highly pure and stable crystalline Form 2 of Bilastine essentially free of other polymorphic forms.
Provided herein are novel, commercially viable and industrially advantageous processes for the preparation of 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one, and its intermediates, in high yield and purity.
The present invention relates to processes for preparation of linezolid crystalline form III. Thus, for example, acetic anhydride (10 ml) is slowly added to the mixture of (S)-N-[[3-[3-fluoro-4-[4-morpholi nyl] phenyl]-2 -oxo-5-oxazol id i nyl] methyl]amine and ethyl acetate at ambient temperature, then stir...
Provided herein are improved, commercially viable and industrially advantageous process for the preparation of primary amine compound by using water as a solvent.
Provided herein are novel, consistently reproducible and industrially advantageous processes for the preparation of iron(III)-based phosphate adsorbent.
Provided herein is a purification process for. producing highly pure Ketorolac tromethamine. Provided also herein is an improved and commercially viable process for the preparation of Ketorolac tromethamine.
Provided herein are novel, commercially viable and industrially advantageous processes for the preparation of a benzimidazole derivative and its intermediates, in high yield and purity.
Disclosed herein are novel, cost effective and industrially advantageous processes for the production of an oxazolidinone antibacterial agent and its intermediate, with a reduced number of synthetic steps, reduction in the chemical waste and thereby increasing the overall yield of the product.
ABSTRACT:
Provided herein is a novel, commercially viable and industrially advantageous processes for the preparation of Bilastine intermediate, methyl 2-[4-(2-chloroethyl)-phenyl]-2-methyl-propanoate, in high yield.
Disclosed herein are novel, cost effective and industrially advantageous processes for the
production of 3-Fluoro-4-(4-mor]Jholinyl)aniline with high yield and purity using cheaper
raw materials and reagents.
Disclosed herein is an improved, cost effective and industrially advantageous process for the production of 4-(4-aminophenyl)-3-morpholinone with high yield and purity using cheaper raw materials and reagents.
Disclosed herein are improved, commercially viable and consistently reproducible processes for the production of highly pure and stable crystalline forms of Apixaban (designated as Form N-1 and H2-2), which are free from other polymorphic forms.
Disclosed herein are consistently reproducible processes for the production of highly pure and stable crystalline Form II of Otilonium bromide essentially free of other polymorphic forms.
Disclosed herein are novel, commercially viable and industrially advantageous processes for the preparation of Bazedoxifene acetate and its intermediates, in high yield and purity. Disclosed also herein are novel, commercially viable and consistently reproducible processes for the preparation of highly pure crystall...
Disclosed herein is an improved, consistently reproducible and commercially viable process for the production of highly pure and stable crystalline Form 1 of Bilastine essentially free of other polymorphic forms.
Disclosed herein is a consistently reproducible process for the production of highly pure and stable crystalline Form II of Carvedilol essentially free of other polymorphic forms.
Disclosed herein is a stable and highly pure crystalline Form 1 of 6-fluoro-3-hydroxypyrazine-2-carboxamide. Disclosed also herein is a novel, consistently reproducible and commercially viable process for the production of highly pure crystalline Form 1 of 6-fluoro-3-hydroxypyrazine-2-carboxamide.
...
Disclosed herein is a novel, commercially viable and industrially advantageous process for the production of 3-Hydroxymethyl-2-(methylamino)pyridine with high yield and purity.
Disclosed herein is an improved, cost effective and industrially advantageous process for the production of 4-Phenyl-3-morpholinone with high yield and high purity.
Provided herein is a novel, commercially viable and industrially advantageous process for the preparation of 4-pST-(5,6-diphenylpyrazm-2-yl)-N-isopropylamino]-1 -butanol.
Disclosed herein is a novel, commercially viable and industrially advantageous process for the preparation of Otilonium bromide in high yield and with high purity.
Provided herein are improved, commercially viable and consistently reproducible processes for the preparation of highly pure crystal Modification I of Rivaroxaban, which is free from other polymorphs and undesired solvated forms. Provided also herein is a highly pure and stable crystal Modification I of Rivaroxaban ...
Disclosed herein are novel, cost effective, consistently reproducible and industrially advantageous processes for the preparation of highly pure Ferric maltol substantially free of genotoxic impurities using water as a solvent. Disclosed also herein is a cost effective, consistently reproducible and industrially adv...
Provided herein is an improved, commercially viable and industrially advantageous process for
the preparation of highly pure Amisulpride.
The present invention relates to novel, commercially viable and industrially advantageous processes for the preparation of Vilanterol intermediates, in high yield and purity.
Disclosed herein is an improved, consistently reproducible and commercially viable process for the production of highly pure and stable crystalline Form III of Lorcaserin hydrochloride hemihydrate essentially free of other polymorphic forms.
Disclosed herein are novel, commercially viable and consistently reproducible processes for the production of highly pure and stable crystalline forms of Ketorolac tromethamine (designated as Form S and Form A), which are free from other polymorphic forms. Disclosed also herein are stable and highly pure crystalli...
Disclosed herein are novel, commercially viable and consistently reproducible processes for the preparation of highly pure and stable crystalline forms of Selexipag, which are free from other polymorphic forms.
Disclosed herein is a novel, commercially viable and industrially advantageous process for the preparation of 2-Amino-5-chloropyridine with high yield and purity.
Disclosed herein is a novel, consistently reproducible, industrially advantageous and commercially viable process for the production of highly pure and stable crystalline Form 1 of Bilastine essentially free of other polymorphic forms.
Provided herein are novel, consistently reproducible and industrially advantageous processes for the preparation of highly pure and stable crystalline Form 4 of Tafamidis essentially free of other polymorphic forms.
Disclosed herein are novel, commercially viable and industrially advantageous processes for the preparation of Edoxaban Tosylate monohydrate and its intermediates. Disclosed also herein is a consistently reproducible and commercially viable process for the production of highly pure crystalline Form I of Edoxaban T...
Disclosed herein are improved, commercially viable and industrially advantageous processes for the preparation of highly pure Vonoprazan or a pharmaceutically acceptable salt thereof, substantially free of impurities, with high yield. Disclosed also herein is a highly pure Vonoprazan or a pharmaceutically acceptable...
Disclosed herein are novel, commercially viable and industrially advantageous processes for the preparation of Finerenone or a pharmaceutically acceptable salt thereof using intermediates with high yield and purity.
Registered Trademarks
[Class : 16] Brochures; Bags [Envelopes, Pouches] Of Paper Or Plastics, For Packaging; Catalogues; Flyers; Folders; Letterheads; Leaflets; Stationery; Periodicals; Manuals; Newsletters; Printed Promotional Materials; Packaging Materials; Packing Materials Of Paper Or Cardboard; Paper; Paper Signboards; Stamp Pads; Stickers; Paper And Cardboard; Printed Matter; Stationery And...
[Class : 16] Brochures; Bags [Envelopes, Pouches] Of Paper Or Plastics, For Packaging; Catalogues; Flyers; Folders; Letterheads; Leaflets; Stationery; Periodicals; Manuals; Newsletters; Printed Promotional Materials; Packaging Materials; Packing Materials Of Paper Or Cardboard; Paper; Paper Signboards; Stamp Pads; Stickers; Paper And Cardboard; Printed Matter; Stationery And...
[Class : 35] Retail And Wholesale Services For Pharmaceutical, Veterinary And Sanitary Preparations And Medical Supplies; Advertisement And Publicity Services Relating To Pharmaceutical, Veterinary And Sanitary Preparations And Medical Supplies; Commercial Information And Advice For Consumers [Consumer Advice Shop] Relating To Pharmaceutical, Veterinary And Sanitary Preparat...
View +3 more Brands for Symed Labs Limited.
Charges
11 July 2007
Andhra Bank
112 Crore
08 February 2016
Tata Cleantech Capital Limited
20 Crore
01 September 2017
Yes Bank Limited
10 Crore
13 June 2013
State Bank Of Mysore
5 Crore
07 October 1999
Andhra Bank
13 Crore
27 September 2011
Andhra Bank
2 Crore
06 May 2011
Andhra Bank
3 Crore
12 December 2008
Andhra Bank
4 Crore
25 September 2023
Others
0
25 September 2023
Others
0
25 September 2023
Others
0
31 January 2022
Others
0
11 July 2007
Others
0
01 September 2017
Yes Bank Limited
0
12 December 2008
Andhra Bank
0
06 May 2011
Andhra Bank
0
27 September 2011
Andhra Bank
0
08 February 2016
Tata Cleantech Capital Limited
0
07 October 1999
Andhra Bank
0
13 June 2013
State Bank Of Mysore
0
25 September 2023
Others
0
25 September 2023
Others
0
25 September 2023
Others
0
31 January 2022
Others
0
11 July 2007
Others
0
01 September 2017
Yes Bank Limited
0
12 December 2008
Andhra Bank
0
06 May 2011
Andhra Bank
0
27 September 2011
Andhra Bank
0
08 February 2016
Tata Cleantech Capital Limited
0
07 October 1999
Andhra Bank
0
13 June 2013
State Bank Of Mysore
0
25 September 2023
Others
0
25 September 2023
Others
0
25 September 2023
Others
0
31 January 2022
Others
0
11 July 2007
Others
0
01 September 2017
Yes Bank Limited
0
12 December 2008
Andhra Bank
0
06 May 2011
Andhra Bank
0
27 September 2011
Andhra Bank
0
08 February 2016
Tata Cleantech Capital Limited
0
07 October 1999
Andhra Bank
0
13 June 2013
State Bank Of Mysore
0
Documents
Form MGT-7-14052021_signed
List of share holders, debenture holders;-29122020
Copy of MGT-8-29122020
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-28122020
XBRL document in respect Consolidated financial statement-28122020
Form AOC-4(XBRL)-28122020_signed
Form CHG-1-05122020_signed
Instrument(s) of creation or modification of charge;-05122020
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20201205
Form PAS-6-01092020_signed
Form DPT-3-06042020-signed
Form MGT-14-11012020_signed
Optional Attachment-(1)-11012020
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-11012020
XBRL document in respect Consolidated financial statement-12122019
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-12122019
Form AOC-4(XBRL)-12122019_signed
Form MGT-7-12122019_signed
Copy of MGT-8-11122019
List of share holders, debenture holders;-11122019
Form DPT-3-29062019
Form CHG-4-10062019_signed
Letter of the charge holder stating that the amount has been satisfied-10062019
Form MSME FORM I-09062019_signed
Form MSME FORM I-08062019_signed
Form AOC-4(XBRL)-17012019_signed
XBRL document in respect Consolidated financial statement-31122018
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-31122018
Copy of MGT-8-29122018
Form MGT-7-29122018_signed
